Abstract
Thomas Bachelot and colleagues describe the use of lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer with brain metastases, in patients not previously treated with either of whole-brain radiotherapy (WBRT), laptanib, or capecitabine. 1 Bachelot T Romieu G Campone M et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013; 14: 64-71 Summary Full Text Full Text PDF PubMed Scopus (490) Google Scholar Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 studyThe combination of lapatinib and capecitabine is active as first-line treatment of brain metastases from HER2-positive breast cancer. A phase 3 trial is warranted. Full-Text PDF Brain metastases from HER2-positive breast cancer – Authors' replyWe thank Carsten Nieder and Sridhar Susheela and colleagues for their thoughtful comments on our study of frontline chemotherapy for brain metastases in patients with HER2-positive metastatic breast cancer.1 Nieder and Susheela rightly point out some of the weakness of our trial, mainly the absence of data regarding neurocognitive function and quality of life. We also could not assess whether a strategy of frontline chemotherapy followed by radiotherapy at progression will result in greater benefit for the patient than an alternative approach, with cerebral radiotherapy before or directly after chemotherapy. Full-Text PDF
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call